Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Other solid neoplasm 5Gastrointestinal 5Dermatologic 5Genitourinary 4CNS 3Head & Neck 2Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1Breast 1

Conditions

Solitary Fibrous Tumor, Pleural 1Mesothelioma, Malignant 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Semaxinib × Thoracic × Clear all
NCT00006014 2013-06-03

SU5416 in Treating Patients With Malignant Mesothelioma

National Cancer Institute (NCI)

Phase 2 Completed
45 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡